Pharmaceutical company staff frequently have questions about the QA/QC process at DCR, as well as our procedures for monitoring medical safety. DCR takes pride in being able to provide timely, reputable results while treating study participants with respect and care for their well-being.
Research participants receive careful evaluation and ongoing medical monitoring through their study participation. Every study participant receives a questionnaire at the end of their study participation to enable him or her to give DCR staff feedback anonymously. Prior study participants consistently report having been very satisfied with their study participation.
DCR has consistently been praised by monitors for CRF and source document quality. Our Study Coordinators are all certified by the Academy of Clinical Research Professionals. Each Coordinator has received extensive training in Good Clinical Practices, the Informed Consent Process, the Protection of Human Research Subjects, as well as laboratory training in phlebotomy, ECG administration and IATA regulations. We work closely with monitors to learn better ways to record information. We develop study-specific source documentation for extra progress notes and phone screens.
Medical Safety QA -- All incoming lab reports and ECG's are first viewed by a study coordinator and then signed and reviewed daily by a physician sub-investigator or PI. Vital signs are monitored at every patient visit. This includes blood pressure, pulse, temperature and weight. DCR study coordinators take turns carrying a pager to give study participants 24-hour medical assistance if needed.
ICF Review -- Two copies of each signed ICF are made at a patient's screening visit. One is given to the patient. The other is given to the PI for internal verification.
CRF - QA -- There is a primary coordinator for each study. Although all coordinators perform patient visits in all studies, the primary coordinator does the data entry. This provides another level of internal QA analysis of data. The same coordinator does not perform the study visit and the data entry.
Source Document Quality -- DCR generates fresh source documents for each new study. The source documents are tailored to match the CRF forms for each study and each visit. Study monitors are also encouraged to offer suggestions or updates to make the source documents as useful and accurate as possible.
"Dr. DuPont,
I am writing this letter to you in response to the Corporate Quality Assurance (CQA) audit that was performed at your site on January 29th and 30th, 2002. I was informed that the audit went very well and that your site was well organized with good attention to protocol adherence and study conduct." |
-- A Clinical Research Specialist
|
DuPont Clinical Research, Inc
Principal Investigator: Caroline DuPont, M.D
DCR STUDIES |
|
|
|
|
|
|
|
DCR # |
|
Company |
|
Type |
|
Year Initiated |
|
|
|
|
|
|
|
| DCR 01 |
|
Merck |
|
Melancholia |
|
2001 |
|
|
|
|
|
|
|
| DCR 02 |
|
GSK |
|
MDD |
|
2001 |
|
|
|
|
|
|
|
| DCR 03 |
|
Merck |
|
Geriatric MDD |
|
2001 |
|
|
|
|
|
|
|
| DCR 04 |
|
Wyeth |
|
Panic |
|
2002 |
|
|
|
|
|
|
|
| DCR 05 |
|
GSK |
|
Depression |
|
2002 |
|
|
|
|
|
|
|
| DCR 06 |
|
Merck |
|
GAD |
|
2002 |
|
|
|
|
|
|
|
| DCR 07 |
|
Wyeth |
|
MDD |
|
2002 |
|
|
|
|
|
|
|
| DCR 08 |
|
Merck |
|
Geriatric MDD |
|
2002 |
|
|
|
|
|
|
|
| DCR 09 |
|
GSK |
|
Seasonal Affective |
|
2002 |
|
|
|
|
|
|
|
| DCR 10 |
|
GSK |
|
Sex. Funct./MDD |
|
2003 |
|
|
|
|
|
|
|
| DCR 11 |
|
Wyeth |
|
MDD |
|
2003 |
|
|
|
|
|
|
|
| DCR 12 |
|
GSK |
|
Geriatric Depr. |
|
2003 |
|
|
|
|
|
|
|
| DCR 13 |
|
GSK |
|
Seasonal Affective |
|
2003 |
|
|
|
|
|
|
|
| DCR 14 |
|
Quintiles |
|
Depr. & Insomnia |
|
2004 |
|
|
|
|
|
|
|
| DCR 15 |
|
Wyeth |
|
MDD Extension |
|
2004 |
|
|
|
|
|
|
|
| DCR 16 |
|
Wyeth |
|
Depression |
|
2004 |
|
|
|
|
|
|
|
| DCR 17 |
|
I3/Lilly |
|
GAD |
|
2004 |
|
|
|
|
|
|
|
| DCR 18 |
|
Merck |
|
Geriatric Insomnia |
|
2004 |
|
|
|
|
|
|
|
| DCR 19 |
|
Cephalon |
|
GAD |
|
2004 |
|
|
|
|
|
|
|
| DCR 20 |
|
Merck |
|
Adult Insomnia |
|
2004 |
|
|
|
|
|
|
|
| DCR 21 |
|
Wyeth |
|
Hot Flash |
|
2004 |
|
|
|
|
|
|
|
| DCR 22 |
|
Cephalon Ext. |
|
GAD |
|
2005 |
|
|
|
|
|
|
|
| DCR 23 |
|
BMS |
|
Bipolar |
|
2005 |
|
|
|
|
|
|
|
| DCR 24 |
|
BMS |
|
Tx Resistant MDD |
|
2005 |
|
|
|
|
|
|
|
| DCR 25 |
|
BMS |
|
Tx Resistant Extens |
|
2006 |
|
|
|
|
|
|
|
| DCR 26 |
|
Sepracor |
|
GAD/Insomnia |
|
2005 |
|
|
|
|
|
|
|
| DCR 27 |
|
Avera |
|
Social Anxiety |
|
2006 |
|
|
|
|
|
|
|
| DCR 28 |
|
Pfizer |
|
Bipolar Mania |
|
2006 |
|
|
|
|
|
|
|
| DCR 29 |
|
I3/Sanofi |
|
MDD |
|
2006 |
|
|
|
|
|
|
|
| DCR 30 |
|
I3/Sanofi |
|
GAD |
|
2006 |
|
|
|
|
|
|
|
| DCR 31 |
|
Wyeth |
|
Hot Flash |
|
2006 |
|
|
|
|
|
|
|
| DCR 32 |
|
BMS |
|
MDD |
|
2006 |
|
|
|
|
|
|
|
| DCR 33 |
|
Wyeth |
|
MDD |
|
2006 |
|
|
|
|
|
|
|
| DCR 34 |
|
Novartis |
|
Depression |
|
2007 |
|
|
|
|
|
|
|
| DCR 35 |
|
Pfizer |
|
Bipolar Depression |
|
2007 |
|
|
|
|
|
|
|
| DCR 36 |
|
Pfizer |
|
Generilzed Anxiety Disorder |
|
2007 |
|
|
|
|
|
|
|
Call us at 301.231.9011.
"Dear Dr. DuPont and Florence:
I am writing to commend you and your site staff on your exemplary recruitment efforts for the [insomnia] trial." |
-- From a project manager 1/20/06
|